BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma

Oncology & Biotech News
Published: Monday, Jul 25, 2011
Antoni Ribas, MD

Antoni Ribas, MD

In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates (ORRs) and durable treatment responses in an open-label phase II study presented at ASCO 2011 by Antoni Ribas, MD, of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.

Table. Patient Baseline Disease Characteristics


Characteristic
No. (%)
N = 132
 
Stage at diagnosis
  M1a
  M1b
  M1c

33 (25)
18 (14)
81 (61)
 
Serum LDH
  Normal
  Elevated

67 (51)
65 (49)
 
No. prior therapies
  1
  2
  3

67 (51)
36 (27)
29 (22)
 
Previous ipilimumab or
tremelimumab
  No
  Yes


125 (95)
7 (5)
 

LDH indicates lactate dehydrogenase.
Adapted from Ribas et al. J Clin Oncol. 2011;29(suppl; abstr 8509).

Patients who had received at least 1 prior line of therapy for metastatic melanoma (49% had received 2 or more) received vemurafenib 960 mg PO BID until progression, unacceptable toxicity, or death. The primary endpoint was ORR by independent review.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.
 
x